Vertex Pharmaceuticals Reports Q3 2026 Financial Results and Raises Full-Year Revenue Guidance

Summary of Event

On November 2, 2026, Vertex Pharmaceuticals Incorporated reported consolidated financial results for the third quarter ended September 30, 2026, via an Item 2.02 Form 8-K.

Key Financial Highlights

• Total Revenue: Reached $3.44 billion in Q3 2026, a 12% increase compared to $3.08 billion in Q3 2025. Growth was driven by cystic fibrosis portfolio performance and diversification into non-CF disease areas.
  • U.S. revenue: $2.17 billion (+10% YoY).
  • International revenue: $1.27 billion (+16% YoY).
• Product Revenue Highlights:
  • CASGEVY: $99 million in Q3 2026 (+30% QoQ).
  • JOURNAVX: $58 million in Q3 2026 (+18% QoQ).
  • PALSONIFY: $10 million in September 2026 following closing of the Crinetics acquisition.
• Net Income:
  • GAAP net income: $654 million (down from $1.1 billion in Q3 2025), primarily reflecting acquisition-related costs.
  • Non-GAAP net income: $1.2 billion (flat YoY).
• Balance Sheet: Cash, cash equivalents, and marketable securities totaled $9.8 billion as of September 30, 2026, compared to $12.3 billion as of December 31, 2025.

Full-Year 2026 Guidance Update

• Total Revenue Guidance: Raised to $13.15 billion – $13.25 billion (previously $13.1 billion – $13.2 billion).
• Combined GAAP R&D, AIPR&D, and SG&A: Adjusted to $7.15 billion – $7.2 billion.
• Combined Non-GAAP R&D, AIPR&D, and SG&A: Approximately $6.0 billion.